Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$13.00
-1.5%
$0.00
$11.06
$63.00
$254.15M1.5235,340 shs61,103 shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$22.39
+1.5%
$20.87
$14.40
$47.00
$1.49B1.13967,075 shs500,675 shs
Innoviva, Inc. stock logo
INVA
Innoviva
$19.28
-1.1%
$19.91
$16.67
$22.00
$1.21B0.37712,899 shs351,059 shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.21
+0.6%
$6.89
$5.01
$17.81
$1.16B2.696.14 million shs4.32 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-1.05%+3.12%-12.00%-98.28%-98.28%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-1.56%-5.57%+7.61%+13.77%-39.99%
Innoviva, Inc. stock logo
INVA
Innoviva
-0.36%-0.41%-7.14%+5.41%+13.44%
Novavax, Inc. stock logo
NVAX
Novavax
+2.43%+2.87%+11.86%+14.72%-48.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.3755 of 5 stars
3.80.00.03.73.31.70.6
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.1633 of 5 stars
4.41.00.00.02.50.00.0
Innoviva, Inc. stock logo
INVA
Innoviva
4.1706 of 5 stars
3.50.00.04.22.71.71.9
Novavax, Inc. stock logo
NVAX
Novavax
4.4215 of 5 stars
3.11.00.04.72.10.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.50
Strong Buy$25.6797.44% Upside
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.89
Moderate Buy$50.11123.83% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$40.33109.15% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.25
Hold$15.86119.81% Upside

Current Analyst Ratings Breakdown

Latest CBIO, INVA, NVAX, and CLDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
Novavax, Inc. stock logo
NVAX
Novavax
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.00
7/14/2025
Innoviva, Inc. stock logo
INVA
Innoviva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
7/14/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$27.00
7/14/2025
Innoviva, Inc. stock logo
INVA
Innoviva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
7/11/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$26.00
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
6/13/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K25,415.00N/AN/A$8.24 per share1.58
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$7.02M211.70N/AN/A$11.26 per share1.99
Innoviva, Inc. stock logo
INVA
Innoviva
$358.71M3.38$3.38 per share5.71$11.03 per share1.75
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.71N/AN/A($3.89) per share-1.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$23.39M-$1.01N/A12.44N/A-16.15%15.77%8.41%7/30/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.7090.180.0638.14%-115.51%29.99%8/14/2025 (Estimated)

Latest CBIO, INVA, NVAX, and CLDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.86N/AN/AN/A$1.13 millionN/A
8/14/2025Q2 2025
Novavax, Inc. stock logo
NVAX
Novavax
-$0.12N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.43N/AN/AN/A$87.10 millionN/A
5/8/2025Q1 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/7/2025Q1 2025
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.25N/A-$0.74N/A$88.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
21.67
21.67
Innoviva, Inc. stock logo
INVA
Innoviva
0.40
2.48
2.30
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
8.70%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
4.40%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million17.85 millionNo Data
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15066.38 million63.46 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.78 million61.36 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable

Recent News About These Companies

13 Cheap Stocks with Huge Upside Potential

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$13.00 -0.20 (-1.52%)
As of 03:44 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$22.39 +0.33 (+1.49%)
Closing price 03:58 PM Eastern
Extended Trading
$22.46 +0.07 (+0.32%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Innoviva stock logo

Innoviva NASDAQ:INVA

$19.28 -0.22 (-1.11%)
Closing price 03:58 PM Eastern
Extended Trading
$19.28 0.00 (-0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.21 +0.04 (+0.61%)
Closing price 03:58 PM Eastern
Extended Trading
$7.16 -0.06 (-0.76%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.